Class information for:
Level 1: ACTIVATION SYNDROME//RISK EVALUATION AND MITIGATION STRATEGIES//REGULATORY ACTIONS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
15807 622 34.6 65%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
667 12573 ANTIDEPRESSANTS//AGOMELATINE//MOCLOBEMIDE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 ACTIVATION SYNDROME Author keyword 7 67% 1% 6
2 RISK EVALUATION AND MITIGATION STRATEGIES Author keyword 4 46% 1% 6
3 REGULATORY ACTIONS Author keyword 3 57% 1% 4
4 FORENS TOXICOL FORENS GENET Address 3 100% 0% 3
5 BLACK BOX WARNINGS Author keyword 3 60% 0% 3
6 N WALES PSYCHOL MED Address 2 36% 1% 5
7 CODISPENSING Author keyword 2 67% 0% 2
8 CONTRAINDICATED Author keyword 2 67% 0% 2
9 HERGEST UNIT Address 2 21% 1% 9
10 PREVENT SCI METHODOL GRP Address 2 31% 1% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class		 LCSH search Wikipedia search
1 ACTIVATION SYNDROME 7 67% 1% 6 Search ACTIVATION+SYNDROME Search ACTIVATION+SYNDROME
2 RISK EVALUATION AND MITIGATION STRATEGIES 4 46% 1% 6 Search RISK+EVALUATION+AND+MITIGATION+STRATEGIES Search RISK+EVALUATION+AND+MITIGATION+STRATEGIES
3 REGULATORY ACTIONS 3 57% 1% 4 Search REGULATORY+ACTIONS Search REGULATORY+ACTIONS
4 BLACK BOX WARNINGS 3 60% 0% 3 Search BLACK+BOX+WARNINGS Search BLACK+BOX+WARNINGS
5 CODISPENSING 2 67% 0% 2 Search CODISPENSING Search CODISPENSING
6 CONTRAINDICATED 2 67% 0% 2 Search CONTRAINDICATED Search CONTRAINDICATED
7 BOXED WARNINGS 1 50% 0% 2 Search BOXED+WARNINGS Search BOXED+WARNINGS
8 CONTRAINDICATED DRUGS 1 50% 0% 2 Search CONTRAINDICATED+DRUGS Search CONTRAINDICATED+DRUGS
9 DEAR DOCTOR 1 100% 0% 2 Search DEAR+DOCTOR Search DEAR+DOCTOR
10 DRUG LABEL CHANGE 1 100% 0% 2 Search DRUG+LABEL+CHANGE Search DRUG+LABEL+CHANGE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DEAR DOCTOR LETTERS 33 100% 2% 13
2 PEDIATRIC SUICIDALITY 25 73% 3% 19
3 CONTRAINDICATED MEDICATIONS 24 91% 2% 10
4 SAFETY WARNINGS 12 86% 1% 6
5 BLACK BOX WARNINGS 5 50% 1% 7
6 PRESCRIPTION RATES 5 50% 1% 7
7 REGULATORY WARNINGS 5 50% 1% 7
8 SSRIS 5 15% 5% 29
9 DRUG ADMINISTRATION DATABASE 4 29% 2% 13
10 SYMPTOM REDUCTION 4 26% 2% 12

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors A Systematic Review 2012 42 46 50%
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials 2005 238 12 50%
Selective serotonin reuptake inhibitors (SSR1s) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review 2005 216 17 47%
Meta-Analysis of Efficacy and Treatment-Emergent Suicidality in Adults by Psychiatric Indication and Age Subgroup Following Initiation of Paroxetine Therapy: A Complete Set of Randomized Placebo-Controlled Trials 2011 11 61 75%
Do SSRIs or antidepressants in general increase suicidality? WPA section on pharmacopsychiatry: consensus statement 2008 31 91 66%
Antidepressant-Induced Suicidality: An Update 2010 17 52 63%
Suicidal Thoughts and Behavior With Antidepressant Treatment Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine 2012 56 14 21%
Impact of Safety-Related Regulatory Action on Clinical Practice A Systematic Review 2012 15 57 51%
A critical review of methods to evaluate the impact of FDA regulatory actions 2013 7 38 32%
Pharmaceutical industry perspective on risk evaluation and mitigation strategies: manufacturer take heed 2012 2 3 100%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 FORENS TOXICOL FORENS GENET 3 100% 0.5% 3
2 N WALES PSYCHOL MED 2 36% 0.8% 5
3 HERGEST UNIT 2 21% 1.4% 9
4 PREVENT SCI METHODOL GRP 2 31% 0.8% 5
5 PHARM BENEFIT MANAGEMENT SERV 1 50% 0.3% 2
6 PHARMACO EPIDEMIOL PHARMACOTHER Y 1 50% 0.3% 2
7 HIGH RISK CONSULTAT CLIN 1 40% 0.3% 2
8 CDK SALZBURG 1 50% 0.2% 1
9 CERTS COORDINATING 1 50% 0.2% 1
10 CIC P 1414 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000217592 BROMATOL NUTR DIETET//ESTADES PRACT TUTELADES UNIT//CLIN PHARMACOL MED CARE
2 0.0000170908 ADOLESCENT DEPRESSION//CHILDRENS DEPRESSION INVENTORY//HEADSPACE EXCELLENCE
3 0.0000121927 SUICIDE//PSYCHOLOGICAL AUTOPSY//STUDY PREVENT SUICIDE
4 0.0000093959 RISK MANAGEMENT STRATEGY//PHARMACOVIGILANCE//MEDDRA
5 0.0000092862 PALINDROMIC RHEUMATISM//RECURRENT ARTHRITIS//INTERMITTENT HYDRARTHROSIS
6 0.0000083116 NORFLUOXETINE//FLUVOXAMINE//CITALOPRAM
7 0.0000073745 VENLAFAXINE//MILNACIPRAN//ESCITALOPRAM
8 0.0000070772 CARDIOVASC METABOL SERV//FORMULARY DEV//SPECIALTY DRUGS
9 0.0000064859 CYCLIC ANTIDEPRESSANT//AMITRIPTYLINE POISONING//TRICYCLIC ANTIDEPRESSANT POISONING
10 0.0000061353 DRUG LAG//OFF PHARMACEUT IND//JAPANESE CLINICAL TRIALS